Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,518 | -3,327 | -18,546 | -14,459 | -9,159 |
| Depreciation Amortization | 285 | 142 | 517 | 377 | 238 |
| Other Working Capital | 629 | -935 | -1,082 | 944 | -319 |
| Other Operating Activity | 1,327 | 183 | 1,037 | 727 | 334 |
| Operating Cash Flow | $-6,277 | $-3,937 | $-18,075 | $-12,411 | $-8,905 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -8 | -4 | -36 | -36 | -31 |
| Investing Cash Flow | $-8 | $-4 | $-36 | $-36 | $-31 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,872 | 6,087 | 15,909 | 14,931 | 7,676 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -136 |
| Financing Cash Flow | $6,872 | $6,087 | $15,909 | $14,931 | $7,540 |
| Beginning Cash Position | 2,768 | 2,768 | 4,968 | 4,968 | 4,968 |
| End Cash Position | 3,355 | 4,914 | 2,768 | 7,453 | 3,573 |
| Net Cash Flow | $587 | $2,146 | $-2,201 | $2,485 | $-1,396 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,277 | -3,937 | -18,075 | -12,411 | -8,905 |
| Capital Expenditure | -8 | -4 | -36 | -36 | -31 |
| Free Cash Flow | -6,285 | -3,941 | -18,110 | -12,447 | -8,936 |